Actively Recruiting
AI-HOPE Lung Cancer: Developing an AI-Based Predictive Tool for Patients with Metastatic Non-Small Cell Lung Cancer Receiving Immunotherapy or Chemo-Immunotherapy
Led by IRCCS San Raffaele · Updated on 2025-01-23
2000
Participants Needed
1
Research Sites
150 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are developing an artificial intelligence (AI) tool to predict responses in patients with metastatic non-small cell lung cancer (NSCLC) receiving immunotherapy or chemo-immunotherapy. The focus is on identifying patients who do not respond early, those at risk of severe toxicities, and those who survive significantly longer than average. The study aims to create a dynamic predictive score that updates as new clinical, laboratory, radiological, and pathological data are collected at specified times. Participants will be divided into two groups based on their treatment: one receiving immunotherapy alone and the other receiving chemo-immunotherapy combinations, both as first-line treatments following clinical practice. Initial data collection will be retrospective, followed by prospective validation. This approach will help understand disease progression, toxicity risks, and long-term survival. Patients will undergo regular follow-up to track disease progression, immune-related lung toxicity, and survival outcomes. The main measures include early disease progression within 8 to 12 weeks, lung toxicity assessed up to 96 months, and survival status at three years. This detailed monitoring aims to improve personalized care and guide treatment decisions by identifying high-risk patients and long survivors.
CONDITIONS
Official Title
AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histological or cytological diagnosis of NSCLC
- Stage IV according to investigator's staging procedures or any locally advanced tumour not suitable for local radical treatment
- Treatment with at least 1 cycle of mono-immunotherapy or chemo-immunotherapy as per clinical practice
- Availability of follow-up
You will not qualify if you...
- Patients with other thoracic tumours non-NSCLC such as small cell lung cancer (SCLC)
- Stage other than IV or feasible for radical treatment upfront
- Treatment within clinical trials using combination regimens different from those specified
- Lost to follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Francesca Rita Ogliari
Milan, Italy, 20132
Actively Recruiting
Research Team
F
Francesca Rita Ogliari, MD
C
Clinical Trial Center OSR
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here